Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

A WORLDWIDE E-INFRASTRUCTURE FOR COMPUTATIONAL NEUROSCIENTISTS (outGRID)

outGRID

FP7 neuGRID (www.neuGRID.eu) is being developed aiming to provide large sets of brain images paired with grid-based computationally intensive algorithms for studies of neurodegenerative diseases. Two infrastructures with similar aims are operational or under construction overseas. In Canada, the Montreal Neurological Institute (MNI) aims to develop...

Funding Programme
Start Date
End Date
Total Funding
€ 491 677
European Countries Involved

ACces to Timely Formal Care

ACTIFcare

In the absence of a cure for dementia, most research is aimed at an early diagnosis as it opens the way to timely future care and treatment, and can help people take control of their lives and plan ahead. However, people with moderate to severe dementia and their carers are often not receiving services of the type, quality and timing that they need...
Funding Programme
Start Date
End Date
Total Funding
€ 2 396 428
European Countries Involved

Active Living For Alzheimer-patients -ALFA

ALPHA

By means of three different technologies, visual stimulation of mirror neurons in Alzheimer patients, an interactive agenda or diary and a movement monitoring system, people with dementia will be able to improve or sustain their cognitive functions. By developing, integrating and testing these technologies in home-care and residential settings we...
Funding Programme
Start Date
End Date
Total Funding
€ 2 162 987
European Countries Involved

ADAMtx: Development of Alzheimer’s immunotherapy by harnessing the natural reparative properties of microglia

ADAMtx

Alzheimer's disease (AD) is a heterogeneous disease in which multiple detrimental factors contribute to cognitive loss and disease escalation. Currently there are no effective therapies for AD. Targeting any single symptom of disease-escalating factor (e.g. amyloid beta, tau, neuroinflammation etc.), even if successful, is not sufficient to modify...
Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Adaptive Implementation and Validation of the positively evaluated Meeting Centers Support Programme for people with dementia and their carers in Europe

MEETINGDEM

MEETINGDEM aims to implement and evaluate the innovative Meeting Centres Support Programme (MCSP) for community dwelling people with dementia and their family carers, in three European countries: Italy, Poland and the United Kingdom. This person-centred approach has been positively evaluated and adaptively implemented in 118 meeting centres in the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 199 819
European Countries Involved

Advancing the non-invasive assessment of brain communication in neurological disease

TrueBrainConnect

Pathological communication between different brain regions has been implicated in various neurological disorders. However, the computational tools for assessing such communication from neuroimaging data are not sufficiently developed. The goal of TrueBrainConnect is to establish brain connectivity analysis using non-invasive electrophysiology as a...
Funding Programme
Start Date
End Date
Total Funding
€ 1 499 875
European Countries Involved

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy

AETIONOMY

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and  (II) the focused application of this pipeline to derive clinically...

Funding Programme
Start Date
End Date
Total Funding
€ 17 546 060

AE_FY2013

Alzheimer Europe (AE) defines its mission as "changing perceptions, practice and policy in order to improve the access of people with dementia and their carers to treatment options and care services". In addition, the organisation has defined its guiding philosophy as "promoting the autonomy and self-determination of people with dementia and their...
Funding Programme
Start Date
End Date
Total Funding
€ 190 000
European Countries Involved

AE_FY2014_FY2013

Alzheimer Europe (AE) defines its mission as "changing perceptions, practice and policy in order to improve the access of people with dementia and their carers to treatment options and care services". In addition, the organisation has defined its guiding philosophy as "promoting the autonomy and self-determination of people with dementia and their...
Funding Programme
Start Date
End Date
Total Funding
€ 285 168
European Countries Involved

affecTive basEd iNtegrateD carE for betteR Quality of Life

TeNDER

With an increasingly growing population in Europe, cognitive impairments as well as heart diseases are a major social and health issue. 1.2 million people in Europe are affected by Parkinson's disease (PD) while Alzheimer’s disease remains one of the biggest global public health challenges our generation is facing, while Cardiovascular disease...
Funding Programme
Start Date
End Date
Total Funding
€ 5 698 333
European Countries Involved

Age-dependent mechanisms of sporadic Alzheimer’s Disease in patient-derived neurons

AGEMEC

Sporadic Alzheimer’s Disease (AD) accounts for the overwhelming majority of all AD cases and exclusively affects people at old age. However, mechanistic links between aging and AD pathology remain elusive. We recently discovered that in contrast to iPSC models, direct conversion of human fibroblasts into induced neurons (iNs) preserves signatures...
Funding Programme
Start Date
End Date
Total Funding
€ 1 499 565
European Countries Involved

Age-modified forms of Amyloid-β as initiator of Alzheimer Disease pathogenesis and mediator of Aβ-tau interaction: a study in a Drosophila model and Aβ immunized human Alzheimer patients

ALZPROTAGEING

Alzheimer Disease (AD) is the commonest form of dementia, with ageing as the main risk factor. There are currently over 6 million people with dementia in the European Union (EU). The increasingly ageing population makes AD an economic and social burden for our society, thus investigating the pathological mechanisms of AD and the characterization of...
Funding Programme
Start Date
End Date
Total Funding
€ 221 606
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).